Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

o conduct a clinical trial in non small cell lung cancer (NSCLC) in patients who have become resistant to platinum therapy. Dr. David Sidransky (Alfacell Chairman of the Board) is spearheading this effort and is in the process of finalizing a special protocol assessment (SPA) which will be presented to the FDA. The patients will be evaluated radiologically for tumor response and will also be evaluated for the time to tumor progression, survival, and side effects of treatment.

Today, other important scientific developments are underway. We are investigating ways to generate revenue from our compounds outside of the clinical and regulatory arena. One such experiment we are looking into is whether Onconase can be used as routine tool to detect the gene silencing via RNA interference (RNAi) mechanism. Currently, there are thousands of researchers interested in finding the answer about the RNAi-mediated gene regulation using their gene of interest. Should we be able to get a positive result, researches from all over the world could be potential buyers of Onconase. We anticipate results shortly.

Other studies will be conducted in order to elucidate if Onconase is able to down regulate the protein produced by the MDR1 gene. There is ample evidence this may be the case, and if so, as previously mentioned, Onconase would be a strong candidate to be used as an adjunct to other chemo therapy regimes.

Of course, our ability to continue with these efforts will depend on our ability to obtain additional financing in the near-term. Talks have been ongoing with potential private investors regarding recapitalizing the company. We cannot assure you, however, that we will be able to secure the necessary financing to maintain the company's operations and pursue these worthwhile projects. It is my sincere hope investors and shareholders alike will see the value in our compounds and continue supporting the company. As I stated earlie
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  According to data released today by the Centers ... Medicare Part D premium is expected to remain stable ... projected, the Pharmaceutical Care Management Association (PCMA) said. ... a bright spot in American health care. By offering ... using cutting edge, cost-saving tools like pharmacy networks and ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
... Pharmaceuticals, Inc. (NYSE: WPI ), today confirmed ... of Delaware has ruled that Watson,s generic version of ... No. 6,264,981 (the ,981 Patent).  The Company said that ... all available options, including an appeal. ...
... 25, 2011 Approximately five percent of prescriptions submitted ... a 30-day period during 2009 included a "dispense as ... patients demand the dispensing of a specific brand-name drug ... care system up to $7.7 billion annually, according to ...
Cached Medicine Technology:Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 3
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, medical ... boosting healthcare market growth, although a reduction in ... generic consumption is a major challenge. , Turkey’s ... having grown at a Compound Annual Growth Rate ... the Health Transformation Program (Saglikta Donus, um Programi, ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... ... ... ... ...
... The U.S. ,race gap, in the commission of violent crime ... arrest rates for African Americans out-distancing those for whites concludes ... University and the University of Oregon. While the gap ... grew again in the ,80s with the advent of crack cocaine. ...
... ... of the New England ADHD Treatment Center are excited to announce a new five week ... ... and Dr. Jeffrey Speller of the New England ADHD Treatment Center are excited to ...
... ... “ADDY” Awards at the 2010 ADDY Awards Ceremony presented in Akron, ... program is the largest advertising competition in the world. With over ... arguably toughest advertising competition. The ADDY Awards represents the true spirit ...
... ... ... , ... , ...
... the rate of growth of the cancer tumour. The standard ... This is the conclusion of scientists at the University of ... The principal reason that patients die of cancer is the ... tumours known as metastases. These metastases are initially so small ...
Cached Medicine News:Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 2Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 3Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 4Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 5Health News:Violent crime 'race gap' narrows, but persists in US 2Health News:Violent crime 'race gap' narrows, but persists in US 3Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 2Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 3Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 2Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 3Health News:Special Session Highlights Late-Breaking Abstracts 2Health News:Special Session Highlights Late-Breaking Abstracts 3Health News:Special Session Highlights Late-Breaking Abstracts 4Health News:Special Session Highlights Late-Breaking Abstracts 5
... The wrap frame is constructed of ... while minimizing potential breakage. The molded ... a full saddle bridge to distribute weight ... peripheral vision with leaded glass side shields. ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
Medicine Products: